Program
TQC3721
A development code. Also written as “TQC3721 suspension for inhalation”, “TQC3721 inhalation powder” and “TQC3721 Suspension for Inhalation”.
In Sino Biopharmaceutical's pipeline, PDE3/4抑制剂
. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 82 open or running | phase 3since Aug 22, 2025 | Aug 17, 2021 | Feb 2027phase 3 · NCT07464587 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQC3721
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2021First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05051930 · 114 enrolled · China
- Mar 15, 2022Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT05292196 · 59 enrolled · China
- Aug 4, 2023Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT05987371 · 75 enrolled · China
- Jul 24, 2024Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06527144 · 240 enrolled · China
- Dec 18, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06748079 · 113 enrolled · China
- Aug 22, 2025Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07147946 · 666 planned · China
- Nov 19, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07252908 · 195 enrolled · China
- Mar 7, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07464587 · 800 planned · China
Ahead
- Feb 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07464587
- Mar 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07147946
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07464587Pulmonary Disease, Chronic Obstructive · China | 3 | Recruiting | Feb 2027 | 800 |
| NCT07252908Pulmonary Disease, Chronic Obstructive · China | 2 | Completed | Apr 28, 2026 | 195 |
| NCT07147946Pulmonary Disease, Chronic Obstructive · China | 3 | Not yet recruiting | Mar 2027 | 666 |
| NCT06748079Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Aug 7, 2026 | 113 |
| NCT06527144Pulmonary Disease, Chronic Obstructive · China | 2 | Completed | Jan 16, 2025 | 240 |
| NCT05987371Pulmonary Disease, Chronic Obstructive · China | 2 | Completed | Jan 16, 2024 | 75 |
| NCT05292196Pulmonary Disease, Chronic Obstructive · China | 2 | Terminated | Jan 11, 2023 | 59 |
| NCT05051930Pulmonary Disease, Chronic Obstructive · China | 1 | UNKNOWN | Oct 31, 2022 | 114 |
How it is read
Names in the registry
- “TQC3721 suspension for inhalation”, 3 entries
- “TQC3721 inhalation powder”, 2 entries
- “TQC3721 Suspension for Inhalation”, 1 entry
- “TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group”, 1 entry
- “TQC3721 Suspension for inhalation”, 1 entry
Codes read as this program: TQC3721.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.